Semaglutide vs. Tirzepatide: Which GLP-1 Is More Effective for Weight Loss?

If you've spent any time researching medical weight loss in 2026, you've encountered two names constantly: semaglutide and tirzepatide. Both are GLP-1 receptor agonists. Both are available as compounded medications through telehealth platforms like LevelsRX. Both work — in clinical trials, remarkably well.

But there are real, clinically meaningful differences between them. Understanding those differences is what allows you to have a productive conversation with your provider and make an informed decision about which medication is appropriate for your situation.

This article breaks down the science without the jargon overload, covers what the actual trial data shows, and explains the practical differences in cost, side effects, and candidate profile.

What Is GLP-1 and How Does It Drive Weight Loss?

GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut produces naturally after you eat. Its primary job is to signal fullness to the brain — telling you that food has arrived and appetite can decrease. It also slows gastric emptying, meaning food moves through your stomach more slowly, extending the feeling of satiety.

GLP-1 receptor agonist medications work by binding to those same receptors and amplifying the signal — far more strongly than the natural hormone does. For most people taking these medications, the result is a dramatic reduction in appetite and what researchers have started calling "food noise" — the persistent mental background chatter about food and eating that drives overconsumption.

The clinical significance of that shift is substantial. People are simply less hungry. Portion control stops being a willpower battle and starts being a physiological reality.

What Is Semaglutide?

Semaglutide is the active ingredient in two FDA-approved brand-name medications:

• Ozempic — approved for type 2 diabetes management, widely used off-label for weight loss
• Wegovy — approved specifically for chronic weight management in adults with obesity or overweight with a weight-related condition

Semaglutide works exclusively through GLP-1 receptor agonism — it activates GLP-1 receptors in the brain and gut, suppressing appetite, slowing digestion, and in people with metabolic conditions, improving blood sugar regulation.

It is administered as a once-weekly subcutaneous injection. An oral formulation of brand-name semaglutide (Rybelsus) also exists, and compounded oral semaglutide is available through platforms like LevelsRX for eligible patients who prefer to avoid injections.

What Is Tirzepatide?

Tirzepatide is the active ingredient in:

• Mounjaro — FDA-approved for type 2 diabetes
• Zepbound — FDA-approved for chronic weight management

What distinguishes tirzepatide from semaglutide is its mechanism. Tirzepatide is a dual agonist — it activates both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. GIP is another gut hormone involved in insulin secretion and fat storage regulation.

The combined activation of both receptor types appears to produce a stronger and more comprehensive metabolic effect than GLP-1 agonism alone, which is reflected in the clinical trial data for weight loss outcomes.

Like semaglutide, tirzepatide is administered as a once-weekly subcutaneous injection. Compounded tirzepatide is available through platforms like LevelsRX when prescribed by a licensed provider.

Clinical Trial Data: How Much Weight Do People Actually Lose?

This is the question most people want answered directly. Here's what the pivotal clinical trials show:

The numbers are clear: tirzepatide outperforms semaglutide on weight loss across virtually every measured endpoint in head-to-head and comparable trial analyses. A 2023 direct comparison study published in JAMA Internal Medicine reinforced this, finding that tirzepatide produced significantly greater weight reduction than semaglutide over 12 months of real-world use.

Side Effects: How Do They Compare?

Both medications share a similar side effect profile because GLP-1 receptor activation affects the gut in similar ways. The most commonly reported side effects for both include:

• Nausea — the most common side effect, especially during dose escalation. Typically peaks in the first 4–8 weeks and diminishes over time for most patients.
• Constipation — caused by reduced gastric motility. Hydration (minimum 64 oz water daily) and dietary fiber significantly reduce severity.
• Vomiting and diarrhea — less common than nausea; more likely during rapid dose increases.
• Fatigue — often related to reduced caloric intake; typically improves as the body adjusts.
• Injection site reactions — mild redness or discomfort, usually transient.

The side effect profiles are broadly similar, but some data suggests tirzepatide may have slightly higher rates of gastrointestinal side effects at higher doses — possibly a reflection of the stronger dual mechanism. However, tolerability for both medications tends to improve significantly after the initial titration period.

Less Common but Important Side Effects

Both medications carry warnings about rare but serious adverse events including pancreatitis, gallbladder disease, and a theoretical risk of thyroid C-cell tumors (observed in rodent studies — not confirmed in humans, but the class warning remains). Neither medication should be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

Cost Comparison: Compounded vs. Brand-Name

The cost gap between brand-name and compounded GLP-1 medications is significant — and it's the primary reason compounded options have grown so rapidly.

Compounded medications are produced during ongoing drug shortages under FDA authorization. The price difference is substantial: brand-name Wegovy can exceed $1,300/month out-of-pocket, while compounded semaglutide through LevelsRX starts at $139/month.

Who Should Choose Which?

Semaglutide may be the better starting point if you:

• Are beginning GLP-1 treatment for the first time and want the well-established option
• Have a strong preference for the lowest possible monthly cost
• Want an oral medication option (compounded oral semaglutide is available at LevelsRX)
• Have a history of needle aversion and are needle-averse
• Have less aggressive weight-loss targets (10–15% body weight)

Tirzepatide may be more appropriate if you:

• Want the strongest evidence-based weight loss outcomes available
• Have metabolic comorbidities (insulin resistance, type 2 diabetes, elevated fasting glucose) that may respond well to the GIP component
• Have significant weight to lose (BMI ≥35) and want to maximize reduction
• Are comfortable with a slightly higher monthly cost for stronger clinical results
• Have previously tried semaglutide and found the results insufficient

The Bottom Line